In patients with advanced or relapsed lung cancers, testing for the presence of epidermal growth factor receptor (EGFR)-sensitizing mutations 5 and the status of anaplastic lymphoma kinase (ALK) gene rearrangements prior to the use of tyrosine kinase inhibitors (TKIs) for therapy has substantially improved survival outcomes 6. This evidence concerns the gene ALK and lung cancer.